E Fund Management (HK)’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

E Fund Management (HK)’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,036	Closed	-$132K	–	505
2025 Q4	$132K	Buy	+1,036	New	+$119K	0.04%	147

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

E Fund Management (HK)'s XBI Position: Q1 2026 in Review

E Fund Management (HK) sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2026, closing a stake of 1,036 shares — an estimated $132K sold.

E Fund Management (HK) first reported a position in XBI in Q4 2025 and held it in 1 quarter. The position peaked at $132K in Q4 2025. 816 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

E Fund Management (HK) reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2026 after selling out during the quarter.
E Fund Management (HK) sold 1,036 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $132K.
E Fund Management (HK) first reported a position in State Street SPDR S&P Biotech ETF in Q4 2025 and held it in 1 quarter.
E Fund Management (HK)'s State Street SPDR S&P Biotech ETF position peaked at $132K in Q4 2025.
816 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on E Fund Management (HK)'s 13F filing for Q1 2026, filed 8 Apr 2026.